Peripheral Neuropathy Trial, Recruiting NCT05763706 Sponsor: Jessa Hospital Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT05763706
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have completed a course of chemotherapy using one or more of the following drugs: paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide, and/or bortezomib
  • People who have been diagnosed with chemotherapy-induced peripheral neuropathy (CIPN) — a type of nerve damage caused by chemotherapy
  • People aged 18 years or older
  • People who do not have a diagnosed or noticeable psychiatric or neurological condition (such as dementia or psychosis) that could interfere with taking part in the study
  • People who speak Dutch
  • People who have signed a form giving their informed consent to participate

Who may not be able to join:

  • People who are currently taking prescription medication at a stable dose specifically for peripheral neuropathy — including gabapentin, pregabalin (Lyrica), nortriptyline, amitriptyline, duloxetine (Cymbalta), or venlafaxine
  • People who have a severe or unstable heart, breathing, or musculoskeletal (bones, muscles, or joints) condition
  • People who miss more than two laser treatment sessions in a row during the trial
  • People with very dark skin tone, classified as skin type VI on the Fitzpatrick scale (confirm with trial site regarding how this is assessed)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jeroen mebis, Prof. Dr., Jessa Hospital

Phone: 011 33 72 21

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Jessa Hospital
Registry
ClinicalTrials.gov
Start date
27 March 2023
Est. completion
15 March 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Modified total neuropathy score (mTNS); Modified total neuropathy score (mTNS); Modified total neuropathy score (mTNS); Pain score; Pain score; Pain score; Mobility score; Mobility score; Mobility score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov